Skip to main content
    I

    Insulet Corporation (PODD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $145.29
    -7.19 (-4.72%)

    Market Cap: $10.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insulet Corporation (PODD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Insulet reported revenue of $2.71B for the fiscal year ended Dec 31, 2025, up 30.7% from the year before. That year, net income was $247.10M with a net margin of 9.1%, operating cash flow was $569.30M and free cash flow was $358.50M. The quarter ended Sep 30, 2026 had revenue of $842.00M and net income of $141.10M.

    Revenue and Margins

    The operating margin was 17.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $366.99M, a compound annual rate of 24.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.71B+30.7%71.6%17.5%9.1%
    Dec 2024$2.07B+22.1%69.8%14.9%20.2%
    Dec 2023$1.70B+30.0%68.3%13.0%12.2%
    Dec 2022$1.31B+18.8%61.7%2.9%0.4%
    Dec 2021$1.10B+21.5%68.4%11.5%1.5%
    Dec 2020$904.40M+22.5%64.4%5.7%0.8%
    Dec 2019$738.20M+30.9%65.1%6.8%1.6%
    Dec 2018$563.80M+21.6%65.7%4.9%0.6%
    Dec 2017$463.80M+26.4%59.8%-1.6%-5.8%
    Dec 2016$366.99MN/A57.5%-2.9%-7.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 40.9% from the year before. In the quarter ended Sep 2026, net income rose 61.1% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.71B$2.07B$1.70B$1.31B$1.10B$904.40M$738.20M$563.80M$463.80M$366.99M
    Cost of revenue$768.20M$625.90M$537.20M$499.70M$346.70M$322.10M$257.90M$193.60M$186.60M$155.90M
    Gross profit$1.94B$1.45B$1.16B$805.60M$752.10M$582.30M$480.30M$370.20M$277.20M$211.09M
    Research and development$301.10M$219.60M$205.00M$180.20M$160.10M$146.80M$132.30M$94.80M$75.70M$55.71M
    Operating income$473.80M$308.90M$220.10M$37.60M$126.00M$51.50M$50.00M$27.40M-$7.40M-$10.70M
    Net income$247.10M$418.30M$206.30M$4.60M$16.80M$6.80M$11.60M$3.30M-$26.80M-$28.88M
    EBITDA$584.70M$391.50M$301.80M$105.50M$221.70M$155.40M$114.40M$71.40M$27.10M$14.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$842.00M$801.70M$761.70M$783.70M$706.30M$649.10M$569.00M$597.50M$543.90M$488.50M$441.70M$509.80M
    Gross profit$632.10M$562.60M$529.10M$568.60M$510.10M$452.20M$409.00M$430.90M$377.10M$330.90M$306.80M$361.20M
    Operating income$189.80M$129.70M$122.10M$146.20M$117.70M$121.10M$88.80M$109.40M$88.10M$54.50M$56.90M$106.50M
    Net income$141.10M$95.00M$91.10M$101.60M$87.60M$22.50M$35.40M$100.70M$77.50M$188.60M$51.50M$103.30M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $949.20M exceeded cash and equivalents by $233.10M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$3.19B$3.09B$2.59B$2.25B$2.05B$1.87B$1.14B$928.70M$816.74M$456.65M
    Current assets$1.91B$1.89B$1.58B$1.31B$1.33B$1.25B$591.00M$461.30M$537.17M$369.96M
    Cash and equivalents$716.10M$953.40M$704.20M$674.70M$791.60M$907.20M$213.70M$113.90M$272.58M$137.17M
    Total liabilities$1.68B$1.88B$1.86B$1.77B$1.49B$1.27B$1.07B$716.60M$658.23M$393.50M
    Short-term debt$18.40M$83.80M$49.40M$27.50M$25.10M$15.60M$0N/A$566.17M$269.00K
    Long-term debt$930.80M$1.30B$1.37B$1.37B$1.25B$1.04B$887.90M$592.00M$566.17M$332.77M
    Shareholder equity$1.52B$1.21B$732.70M$476.40M$556.30M$603.60M$75.90M$212.10M$158.52M$63.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$3.42B$3.17B$2.99B$3.19B$3.03B$3.47B$3.52B$3.09B$3.03B$2.88B$2.62B$2.59B
    Total liabilities$1.84B$1.74B$1.68B$1.68B$1.65B$2.01B$2.19B$1.88B$1.91B$1.88B$1.83B$1.86B
    Cash and equivalents$584.40M$534.90M$480.40M$716.10M$757.40M$1.12B$1.28B$953.40M$902.60M$821.00M$751.20M$650.70M
    Shareholder equity$1.58B$1.42B$1.30B$1.52B$1.38B$1.46B$1.33B$1.21B$1.12B$998.40M$790.70M$732.70M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 63.0% of operating cash flow. Share repurchases came to 16.6% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$569.30M$430.20M$145.70M$119.00M-$68.10M$84.00M$98.40M$35.90M$41.30M$15.91M
    Capital expenditures$210.80M$134.00M$84.10M$135.80M$122.70M$166.50M$163.70M$157.40M$73.80M$22.11M
    Free cash flow$358.50M$296.20M$61.60M-$16.80M-$190.80M-$82.50M-$65.30M-$121.50M-$32.50M-$6.20M
    Dividends paidN/AN/A$10.60MN/A$23.50M$98.50M$8.60MN/A$0$0
    Share repurchases$59.60M$0$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$222.70M-$146.20M-$119.40M-$191.10M-$82.70M$14.00M-$73.60M-$184.50M-$210.80M-$178.01M
    Financing cash flow-$595.30M-$28.00M-$13.60M-$40.30M$40.70M$605.50M$73.50M-$8.70M$304.50M$176.57M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$123.50M$88.40M$113.80M$183.30M$125.70M$196.50M$63.80M$147.50M$108.30M$86.80M$87.60M$45.20M
    Capital expenditures$61.90M$37.30M$27.80M$140.80M$31.10M$23.20M$15.70M$56.00M$29.10M$24.90M$24.00M$31.60M
    Free cash flow$61.60M$51.10M$86.00M$42.50M$94.60M$173.30M$48.10M$91.50M$79.20M$61.90M$63.60M$13.60M
    Last 12 quarters

    Frequently Asked Questions About PODD

    What is Insulet's annual revenue?

    Insulet reported revenue of $2.71B for the fiscal year ended Dec 31, 2025.

    How fast is Insulet's revenue growing?

    Revenue was up 30.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 27.5%.

    Is Insulet profitable?

    Yes. Insulet reported net income of $247.10M for the fiscal year ended Dec 31, 2025, with a net margin of 9.1%.

    How much free cash flow does PODD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $569.30M minus capital expenditures of $210.80M produced free cash flow of $358.50M.

    How much debt does Insulet have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $930.80M, short-term debt of $18.40M and cash and equivalents of $716.10M.